• The FDA approved Imcivree (setmelanotide) for acquired hypothalamic obesity.
• The label covers adults and pediatric patients aged 4 years and older, for long-term reduction and maintenance of excess body weight.
• Approval was supported by the Phase 3 TRANSCEND trial (N=142), which reported an -18.4% placebo-adjusted BMI reduction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603191830PRIMZONEFULLFEED9675670) on March 19, 2026, and is solely responsible for the information contained therein.